Immunohistochemical analysis identifies two cyclin D1+subsets of plasma cell myeloma, each associated with favorable survival

被引:37
作者
Cook, JR
Hsi, ED
Worley, S
Tubbs, RR
Hussein, M
机构
[1] Cleveland Clin Fdn, Dept Clin Pathol, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA
[3] Cleveland Clin Fdn, Multiple Myeloma Program, Cleveland, OH 44195 USA
关键词
cyclin D1; immunohistochemistry; myeloma; prognosis;
D O I
10.1309/BDR959TT4JU6388C
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The significance of cyclin D1 expression in plasma cell myeloma was examined by immunohistochemical analysis using a newly available rabbit monoclonal antibody with superior staining properties. Two patterns of positive staining were observed, each associated with distinct pathologic features. Strong cyclin D1 staining was associated with increased plasma cells at diagnosis (P = .026), lymphoplasmacytic morphologic features (P = .029), CD20 expression (P = .040), and t(11; 14)(q13;q32) as detected by interphase fluorescence in situ hybridization with simultaneous CD138 immunofluorescence (P < .001). In contrast, weak staining was associated with hyperdipoidy (P = .02) and gains of the CCND1 locus (P = .01). Overall survival was longer in the cyclin. D1 + cases than. in cyclin D1- cases (estimated 3-year survival, 73% vs 27%; P = .005). Improved survival was seen in the strongly Positive and weakly positive groups compared with cyclin D1-cases (P = .005). This report shows for the first time that cyclin D1 immunohistochemical analysis can provide prognostic information in. plasma cell myeloma.
引用
收藏
页码:615 / 624
页数:10
相关论文
共 30 条
[1]  
Athanasiou E, 2001, AM J CLIN PATHOL, V116, P535
[2]   Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation [J].
Avet-Loiseau, H ;
Facon, T ;
Grosbois, B ;
Magrangeas, F ;
Rapp, MJ ;
Harousseau, JL ;
Minvielle, S ;
Bataille, R .
BLOOD, 2002, 99 (06) :2185-2191
[3]  
Barille-Nion Sophie, 2003, Hematology Am Soc Hematol Educ Program, P248
[4]   HISTOLOGIC CLASSIFICATION AND STAGING OF MULTIPLE-MYELOMA - A RETROSPECTIVE AND PROSPECTIVE-STUDY OF 674 CASES [J].
BARTL, R ;
FRISCH, B ;
FATEHMOGHADAM, A ;
KETTNER, G ;
JAEGER, K ;
SOMMERFELD, W .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1987, 87 (03) :342-355
[5]   Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma [J].
Bergsagel, PL ;
Kuehl, WM ;
Zhan, FH ;
Sawyer, J ;
Barlogie, B ;
Shaughnessy, J .
BLOOD, 2005, 106 (01) :296-303
[6]   Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma [J].
Bergsagel, PL ;
Kuehl, WM .
IMMUNOLOGICAL REVIEWS, 2003, 194 (01) :96-104
[7]   Chromosome translocations in multiple myeloma [J].
Bergsagel, PL ;
Kuehl, WM .
ONCOGENE, 2001, 20 (40) :5611-5622
[8]   The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant [J].
Chang, H ;
Sloan, S ;
Li, D ;
Zhuang, LH ;
Yi, QL ;
Chen, CI ;
Reece, D ;
Chun, K ;
Stewart, AK .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (01) :64-68
[9]   Consistent immunostaining for cyclin D1 can be achieved on a routine basis using a newly available rabbit monoclonal antibody [J].
Cheuk, W ;
Wong, KOY ;
Wong, CSC ;
Chan, JKC .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2004, 28 (06) :801-807
[10]   Clinical and biologic implications of recurrent genomic aberrations in myeloma [J].
Fonseca, R ;
Blood, E ;
Rue, M ;
Harrington, D ;
Oken, MM ;
Kyle, RA ;
Dewald, GW ;
Van Ness, B ;
Van Wier, SA ;
Henderson, KJ ;
Bailey, RJ ;
Greipp, PR .
BLOOD, 2003, 101 (11) :4569-4575